How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,901 results for

Imiquimod

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1701. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Full Text available with Trip Pro

Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Topical application of the immune response modifier imiquimod is an alternative approach for the treatment of human papillomavirus (HPV)-positive vulvar intraepithelial neoplasia (VIN) and aims at the immunologic eradication of HPV-infected cells. We have charted HPV16-specific immunity in 29 (...) patients with high-grade VIN and examined its role in the clinical effect of imiquimod treatment.The magnitude and cytokine polarization of the HPV16 E2-, E6-, and E7-specific CD4+ T-cell response was charted in 20 of 29 patients by proliferation and cytokine bead array. The relation between HPV16-specific type 1 T-cell immunity and imiquimod treatment was examined in a group of 17 of 29 patients.HPV16-specific proliferative responses were found in 11 of the 20 patients. In eight of these patients, T

2005 Clinical Cancer Research

1702. Angiolymphoid hyperplasia with eosinophilia successfully treated with imiquimod. A case report. (Abstract)

Angiolymphoid hyperplasia with eosinophilia successfully treated with imiquimod. A case report. Angiolymphoid hyperplasia with eosinophilia (ALHE) is a rare disorder characterized by vascular proliferation, eosinophilia in peripheral blood samples and lymphocytosis. The etiology is unknown; this rare condition is generally seen in women. It often presents as multiple, grouped red nodules in the periauricular region, scalp line and neck. Numerous therapeutic approaches have been tried for ALHE (...) including destructive techniques such as electrodesiccation, cryotherapy, surgical excision, radiotherapy or laser (argon, CO(2), pulse dye). We present an ALHE case that was treated successfully by using topical imiquimod cream.Copyright 2007 S. Karger AG, Basel.

2007 Dermatology

1703. Multiple and clustered eruptive epidermoid cysts following treatment with topical imiquimod. (Abstract)

Multiple and clustered eruptive epidermoid cysts following treatment with topical imiquimod. A 61-year-old woman developed multiple and clustered eruptive epidermoid cysts at the site of treatment of a basal cell carcinoma located on her nose with imiquimod 5% cream (5 times/week for 6 weeks). Clearing was achieved after topical treatment with tretinoin 0.025% cream (1 application/day for 1 month).2007 S. Karger AG, Basel

2007 Dermatology

1704. Pyogenic granuloma in children: Treatment with topical imiquimod. (Abstract)

Pyogenic granuloma in children: Treatment with topical imiquimod. We report the successful treatment of five children with facial pyogenic granuloma using topical imiquimod 5% cream. In all cases, resolution of the lesions was achieved within 2-4 weeks. Local erythema and scaling, consistent with a typical imiquimod response, was the most commonly observed side effect. No systemic complications were observed in any of the patients. There has been no recurrence of any of the lesions to date

2007 Australasian Journal of Dermatology

1705. Human papillomavirus-type predict the clinical outcome of imiquimod therapy for women with vulvar condylomata acuminata. (Abstract)

Human papillomavirus-type predict the clinical outcome of imiquimod therapy for women with vulvar condylomata acuminata. To investigate the effect of determination of human papillomavirus (HPV) subtype on the success of imiquimod therapy in women with vulvar condylomata acuminata.A total of 132 women with biopsy-proven vulvar condylomata acuminata were enrolled in this prospective study. HPV DNA detection and determination of genotype were made through polymerase chain reaction (PCR) technique (...) . The women were treated with imiquimod cream 5% in the area of the visible lesions, three times a week at night for 16 weeks.Twelve of the 132 women (9.1%) failed to detect any improvement with this therapy during the 16-week period. However, 80 women (60.6%) experienced total clearance of the lesions, and 20 women (15.2%) observed a partial response. The complete response rates were 76.2% for HPV-6, 66.7% for HPV-11, 35% for HPV-6 plus 11, and 6.3% for unclassified HPV subtypes (other HPV subtypes than

2007 Acta Obstetricia et Gynecologica Scandinavica

1706. Preliminary results of 5% imiquimod cream in the primary treatment of vulva intraepithelial neoplasia grade 2/3. (Abstract)

Preliminary results of 5% imiquimod cream in the primary treatment of vulva intraepithelial neoplasia grade 2/3. This study was undertaken to study the tolerability and efficacy of 5% imiquimod cream in the primary treatment of vulva intraepithelial neoplasia (VIN) grade 2/3.VIN grade 2/3 patients were recruited from regional colposcopy units. Imiquimod cream was applied over the abnormal area by the patient using an escalating dose regime for total treatment duration of 16 weeks. At the end

2006 American Journal of Obstetrics and Gynecology

1707. Effectiveness of imiquimod 5% cream for treatment of extensive anogenital warts in a seven-year-old child. (Abstract)

Effectiveness of imiquimod 5% cream for treatment of extensive anogenital warts in a seven-year-old child. Conventional treatment options for anogenital warts in prepubertal children rely on chemical and physical destruction methods that can be difficult and painful and frequently require the use of general anesthesia. Other approaches include the use of immunotherapies, as topical imiquimod and intralesional or systemic interferon. We report a 7-year-old girl with extensive anogenital warts (...) who was successfully treated with topical 5% imiquimod cream.

2007 Pediatric Infectious Dsease Journal

1708. Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma. (Abstract)

Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma. To evaluate the efficacy and safety of topical imiquimod 5% cream for the treatment of eyelid basal cell carcinoma.Two interventional case reports.Imiquimod 5% cream was applied topically once daily, 3 days a week for 8 to 12 weeks, in two patients affected by eyelid nodular basal cell carcinoma. Patients were followed up clinically with slit-lamp examination for evidence of tumor disappearance or recurrence (...) , and local and systemic side effects.Complete clinical response was obtained in both patients. No severe local side effects were observed. Patients did not show any local recurrence after 1 year.Topical imiquimod 5% cream seems to be a useful treatment for eyelid nodular basal cell carcinoma in selected cases, but further long-term studies are needed to assess the efficacy and safety of this approach.

2005 American Journal of Ophthalmology

1709. Progressive ORF virus infection in a patient with lymphoma: successful treatment using imiquimod. Full Text available with Trip Pro

Progressive ORF virus infection in a patient with lymphoma: successful treatment using imiquimod. Orf virus is a parapoxvirus that infects small ruminants worldwide. We present the case report of a 73-year-old woman with non-Hodgkins lymphoma who developed progressive orf virus lesions that were unresponsive to surgical debridement and to cidofovir therapy. The patient's orf virus infection was successfully treated with topical imiquimod despite progression of her malignancy.

2007 Clinical Infectious Diseases

1710. Selective defect in plasmacyoid dendritic cell function in a patient with AIDS-associated atypical genital herpes simplex vegetans treated with imiquimod. Full Text available with Trip Pro

Selective defect in plasmacyoid dendritic cell function in a patient with AIDS-associated atypical genital herpes simplex vegetans treated with imiquimod. We report a case of acquired immunodeficiency syndrome (AIDS)-associated, acyclovir-refractory genital herpes infection treated with topical imidazoquinoline therapy. The patient's plasmacytoid dendritic cells made a robust interferon- alpha response following in vitro stimulation with imidazoquinoline but not with herpes simplex virus. We

2007 Clinical Infectious Diseases

1711. Successful treatment of intranasal papillomata with imiquimod cream in a human immunodeficiency virus positive patient. (Abstract)

Successful treatment of intranasal papillomata with imiquimod cream in a human immunodeficiency virus positive patient. To report a new, alternative treatment for nasal papillomata in human immunodeficiency virus positive patients with multiple recurrences after surgical removal.A human immunodeficiency virus positive patient presented with multiple, recurrent nasal papillomata which developed after repeated surgical removal procedures. In this patient, complete and persistent resolution (...) of the lesions was achieved after topical treatment with imiquimod cream.Imiquimod is a class of non-nucleoside imidazoquinolinamines which promotes local cytokine release from antigen-presenting cells inducing a T-h1 dominant cell-mediated response against virus-infected cells. Topical imiquimod 5 per cent cream, applied for four to 16 weeks, may offer some benefit in the management of recurrent nasal papillomata in human immunodeficiency virus positive patients. Such treatment may be preferable to surgery

2008 Journal of Laryngology & Otology

1712. Involution of infantile haemangiomas after imiquimod 5% cream. Full Text available with Trip Pro

Involution of infantile haemangiomas after imiquimod 5% cream. Infantile haemangioma is a common childhood condition, which usually resolves spontaneously and is managed expectantly. In a small percentage of complex cases, haemangiomas may be associated with complications such as persistent bleeding, ulceration, feeding difficulties or visual impairment. Active treatment is often necessary in such cases. Current interventions include surgical, laser and immunomodulatory treatments. Imiquimod 5 (...) % cream is a novel alternative topical treatment that may have a potential role in management of these patients. We present our experience of imiquimod 5% cream in the treatment of five children with difficult haemangiomas. We discuss its efficacy and some of the side effects that may be encountered, which have not previously been reported.

2008 Clinical & Experimental Dermatology

1713. Cryosurgery during topical imiquimod: a successful combination modality for lentigo maligna. (Abstract)

Cryosurgery during topical imiquimod: a successful combination modality for lentigo maligna. Either cryosurgery or topical imiquimod have been used to treat patients with lentigo maligna in cases where surgery is not feasible.We report a patient with lentigo maligna, who was treated with the combination of topical imiquimod and cryosurgery, and review the rationale, which led us to design the present combined cryo-immunological treatment modality.Sustained clearance of lentigo maligna to date (...) (26 months after treatment). The successful treatment of this patient was based on the following rationale: A cryosurgery session during continuing imiquimod application may: (i) reinforce apoptosis of tumor cells; (ii) strengthen antiangiogenesis in the treated tumor; and (iii) build-up a potent tumor-destructive immune response by a cascade of events starting with imiquimod-promoted attraction of immature dendritic antigen-presenting cells (DCs) into the tumor. DCs further mature within

2008 International Journal of Dermatology

1714. Pyogenic granuloma: complete remission under occlusive imiquimod 5% cream. (Abstract)

Pyogenic granuloma: complete remission under occlusive imiquimod 5% cream. An 82-year-old man was referred to our department for evaluation and treatment of a recurrent pyogenic granuloma on his right hand. After previous histopathological confirmation of the clinical diagnosis, he had been treated twice with electrocautery, but the lesion recurred 10 and 8 days later, respectively. After a 3-week topical application of imiquimod 5% cream twice daily under occlusion, complete remission

2008 Clinical & Experimental Dermatology

1715. Imiquimod Leads to a Decrease of Human Papillomavirus DNA and to a Sustained Clearance of Anal Intraepithelial Neoplasia in HIV-Infected Men. Full Text available with Trip Pro

Imiquimod Leads to a Decrease of Human Papillomavirus DNA and to a Sustained Clearance of Anal Intraepithelial Neoplasia in HIV-Infected Men. Anal intraepithelial neoplasia (AIN), a human papillomavirus (HPV)-associated precursor lesion of anal carcinoma, is highly prevalent in HIV-infected men having sex with men (MSM). This prospective follow-up study evaluated the long-term results of imiquimod treatment of AIN in 19 HIV-infected MSM. Standardized follow-up examinations included high (...) ) developed new anal cytological abnormalities in previously normal, untreated anal regions. 55% of these new AIN lesions were high-grade lesions and most of them were located intra-anally and associated with high-risk HPV types not detectable before therapy. These results demonstrate that imiquimod leads to a high rate of long-term clearance of AIN in HIV-positive men together with a prolonged decrease of high-risk HPV-DNA load. However, new AIN lesions associated with previously undetected HPV types

2008 Journal of Investigative Dermatology

1716. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. Full Text available with Trip Pro

Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. Melanoma lesions can be frozen in vivo, resulting in necrotic death of malignant cells and in tumor antigen release suitable for cross-presentation by professional antigen-presenting cells. Imiquimod is a small molecule with adjuvant pro-inflammatory effects that can be topically delivered as a cream. Local cryosurgery of B16/ovalbumin (OVA)-derived subcutaneous tumor nodules leads (...) to curative destruction of the lesions. If imiquimod is repeatedly applied on the cryo-treated lesion, a conspicuous, leukocyte-rich inflammatory infiltrate appears during the days following treatment. Mice treated by cryosurgery plus imiquimod rejected rechallenges of B16/OVA in 90% of the cases, whereas cryosurgery alone failed to prevent tumor grafting in 70% of the cases. The combination treatment of B16/OVA tumors was also able to protect 60% of the mice against outgrowth of a lethal dose of non

2007 Journal of Investigative Dermatology

1717. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. Full Text available with Trip Pro

The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. Imiquimod, a small-molecule immune response modifier of the imidazoquinoline family, has shown profound antitumoral and antiviral efficacy both in vitro and in clinical applications in vivo. It has been demonstrated that this activity is mediated through the Toll-like receptor (TLR)7- and TLR8-signaling cascade resulting in the secretion (...) of proinflammatory cytokines and, consecutively, induction of a tumor-directed cellular immune response. In addition, imiquimod exerts a direct proapoptotic activity in tumor cells. We demonstrate here that imiquimod induces activation of the transcription factor NF-kappaB and the downstream production of proinflammatory cytokines in the absence of TLR7 and TLR8. In Chinese hamster ovary cells stably transfected with the human adenosine receptor subtypes, we then show in radioligand-binding competition

2006 Journal of Investigative Dermatology

1718. Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance. Full Text available with Trip Pro

Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance. Imiquimod (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine) is a TLR7 agonist that induces cytokine production in TLR7 bearing antigen-presenting cells (APCs), including IL-12, a cytokine that has been demonstrated to be a critical effector molecule for contact hypersensitivity (CHS). To test our hypothesis that topical applications of imiquimod may protect the skin immune system (...) against the deleterious effects of UV light exposures, we treated animals with this agent, or its vehicle or nothing before UV exposures. Although topical imiquimod exposures before UV light did not prevent the depletion of epidermal Langerhans cells, it did prevent the loss of CHS. IL-12 was important in the protective role of imiquimod in preventing UV-induced loss of CHS, as systemic treatment of mice with an anti-IL-12 p70 monoclonal antibody blocked the protective effects of imiquimod

2006 Journal of Investigative Dermatology

1719. Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. (Abstract)

Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. In the USA, Imiquimod 5% cream is approved for use 2-3 times per week over 16 weeks for the treatment of actinic keratoses (AKs). This study evaluated the efficacy of imiquimod in another treatment schedule, for AKs on the head.Open-label, phase IIIb.180 dermatology clinics and practices in Germany.Patients were eligible if they had clinically typical (...) in the treatment area at the course 1 or course 2 post-treatment visit.829 patients entered the study. Overall, the complete clearance rate was 68.9% (571/829) and the partial clearance rate (percentage of patients with >/= 75% reduction in the number of baseline AK lesions) was 80.2%. Local skin reactions (LSRs) and application site reactions (ASRs) were the most commonly reported adverse events. Four patients discontinued from the study due to LSRs or ASRs.Shorter treatment regimen of imiquimod 5% cream can

2007 British Journal of Dermatology

1720. Evaluation of imiquimod for the therapy of external genital and anal warts in comparison with destructive therapies. (Abstract)

Evaluation of imiquimod for the therapy of external genital and anal warts in comparison with destructive therapies. External genital and anal warts (acuminate condyloma) were the first medical indication the topical immune response modifier imiquimod was approved for in 1997. Since then, many placebo controlled randomized clinical trials have demonstrated the efficacy and safety of this synthetic imidazoquinoline derivate for the treatment of different human papillomavirus infections (...) and tumours. Treatment modalities for genital warts (5% cream, three times weekly, minimum duration 4 weeks, control of side-effects) have been optimized and assured by further clinical trials and meta-analyses. For a few years clinical studies focussed on the long-term efficacy of the immunomodulatory therapy (sustained clearance from warts) and most recent studies compared the efficacy of ablative, destructive and imiquimod monotherapy as well as combination therapies.

2007 British Journal of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>